Literature DB >> 8564320

A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia.

J Cottraux1, I D Note, C Cungi, P Légeron, F Heim, L Chneiweiss, G Bernard, M Bouvard.   

Abstract

BACKGROUND: This multicentre study compared a 16-week buspirone treatment with placebo in patients presenting with panic disorder with agoraphobia and also receiving cognitive behaviour therapy (CBT).
METHOD: Double-blind testing was maintained until week 68, but not tested; 91 patients were included; 14 placebo-responders excluded; 77 patients randomised; 48 reached week 16 and 41 reached week 68.
RESULTS: At week 16, within-group analysis showed significant improvements in agoraphobia, panic attacks, and depression in both groups. Generalised anxiety improved only in CBT+buspirone. Between-group comparisons showed buspirone to have an effect on generalised anxiety and agoraphobia. Changes in degree of agoraphobia and depression were correlated in subjects on CBT+buspirone only. A significantly higher proportion of women, and of subjects showing high avoidance dropped out. Positive expectations regarding medication predicted success in both groups. At week 68, improvement was retained without significant buspirone effect.
CONCLUSION: Buspirone enhanced the effects of cognitive behaviour therapy on generalised anxiety and agoraphobia in the short term.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8564320     DOI: 10.1192/bjp.167.5.635

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  4 in total

1.  Molecular dynamics of 5-HT1A and 5-HT2A serotonin receptors with methylated buspirone analogues.

Authors:  A Bronowska; Z Chilmonczyk; A Leś; O Edvardsen; R Ostensen; I Sylte
Journal:  J Comput Aided Mol Des       Date:  2001-11       Impact factor: 3.686

Review 2.  Panic disorder.

Authors:  Shailesh Kumar; Darren Malone
Journal:  BMJ Clin Evid       Date:  2008-12-16

Review 3.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

4.  Nonpharmacological treatments for anxiety disorders.

Authors:  Jean Cottraux
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.